FOXD2 and esophageal squamous cell carcinoma: Moreover, FOXD2-AS1 increases the cisplatin resistance (6.25, 12.5, 25, 50, and 100 μg/mL) by promoting the Akt/mTOR axis stimulation in ESCC cells [62] (Table 1).